by tim » Sun May 17, 2026 12:17 pm
https://jonfleetwood.substack.com/p/lou ... rst-in-the
Louisiana to Vote on First-in-the-Nation Resolution Backing Fenbendazole for Cancer Treatment
HR 174 encourages state health officials to examine fenbendazole’s cancer-fighting potential as studies and patient reports fuel growing demand for expanded access.
The Louisiana House of Representatives is scheduled to vote Monday on a first-in-the-nation resolution urging the state surgeon general and Louisiana Department of Health to formally assess fenbendazole as a potential treatment for cancer in humans and develop recommendations for engaging federal regulators on expedited review pathways.
House Resolution 174 (HR 174), sponsored by State Representative Charles Owen (R-30), passed the House Committee on Health and Welfare unanimously in a 10-0 vote and is now scheduled for floor debate on May 18, 2026.
The measure represents a major health freedom milestone, signaling growing willingness among lawmakers to challenge traditional gatekeeping around experimental and repurposed therapies—especially for patients facing life-threatening illnesses with limited treatment options.
If adopted, the HR 174 would formally request that Louisiana’s top public health officials evaluate whether fenbendazole could potentially be advanced toward human authorization for cancer treatment or other conditions and determine what state-level actions could support additional scientific review.
You can contact your Louisiana House representatives here to urge them to vote yes on HR 174 and pass this first-of-its-kind resolution.
https://fenbendazole.substack.com/
https://fenbendazole.substack.com/p/the ... paper-that
Updated: They Retracted the 2025 Paper That Proved Fenbendazole Cures Cancer
Here’s Why That Tells You Everything.
The “Reason” — and Why It Is Fabricated
The retraction was ordered by the journal’s Editor, Dr. Maurie Markman, on the grounds that Dr. Makis had an undeclared financial interest — specifically, that at the time of submission he offered services related to the topic of the study, i.e., he treats cancer patients with fenbendazole. The retraction statement noted that “the author’s response when contacted were found to be unsatisfactory” and concluded that “these concerns would have affected the interpretation of the work” (Case Reports in Oncology, 2026).
Read that again and let it sink in.
Fenbendazole is an off-patent, over-the-counter veterinary antiparasitic. It costs pennies per dose. No pharmaceutical company owns exclusive rights to it. No one profits handsomely from its use. As reviewed by Nguyen et al. (2024), fenbendazole’s patent expired in the early 1990s, making it available as a generic drug accessible through animal supply stores and online platforms. The “financial interest” claimed against Dr. Makis — a physician helping patients with a drug that generates essentially no revenue — is not just weak. It is nonsensical.
Now let’s talk about who Dr. Markman actually is and who actually has a financial conflict of interest here.
The Real Conflict of Interest
Dr. Maurie Markman is the President of Medicine and Science at City of Hope Cancer Center. City of Hope is a multi-billion-dollar cancer treatment enterprise that generates its revenue from — you guessed it — cancer treatment. Expensive cancer treatment. Patented cancer treatment. Chemotherapy, immunotherapy, targeted biologics: treatments that cost hundreds of thousands of dollars per patient per year, that are frequently toxic, that often extend life by only weeks to months, and that leave behind a devastating legacy of cancer stem cells that drive relapse and metastasis.
[url]https://jonfleetwood.substack.com/p/louisiana-to-vote-on-first-in-the[/url]
[quote]Louisiana to Vote on First-in-the-Nation Resolution Backing Fenbendazole for Cancer Treatment
HR 174 encourages state health officials to examine fenbendazole’s cancer-fighting potential as studies and patient reports fuel growing demand for expanded access.[/quote]
[quote]The Louisiana House of Representatives is scheduled to vote Monday on a first-in-the-nation resolution urging the state surgeon general and Louisiana Department of Health to formally assess fenbendazole as a potential treatment for cancer in humans and develop recommendations for engaging federal regulators on expedited review pathways.
House Resolution 174 (HR 174), sponsored by State Representative Charles Owen (R-30), passed the House Committee on Health and Welfare unanimously in a 10-0 vote and is now scheduled for floor debate on May 18, 2026.
The measure represents a major health freedom milestone, signaling growing willingness among lawmakers to challenge traditional gatekeeping around experimental and repurposed therapies—especially for patients facing life-threatening illnesses with limited treatment options.
If adopted, the HR 174 would formally request that Louisiana’s top public health officials evaluate whether fenbendazole could potentially be advanced toward human authorization for cancer treatment or other conditions and determine what state-level actions could support additional scientific review.
You can contact your Louisiana House representatives here to urge them to vote yes on HR 174 and pass this first-of-its-kind resolution.[/quote]
[url]https://fenbendazole.substack.com/[/url]
[url]https://fenbendazole.substack.com/p/they-retracted-the-2025-paper-that[/url]
[quote]Updated: They Retracted the 2025 Paper That Proved Fenbendazole Cures Cancer
Here’s Why That Tells You Everything.[/quote]
[quote]The “Reason” — and Why It Is Fabricated
The retraction was ordered by the journal’s Editor, Dr. Maurie Markman, on the grounds that Dr. Makis had an undeclared financial interest — specifically, that at the time of submission he offered services related to the topic of the study, i.e., he treats cancer patients with fenbendazole. The retraction statement noted that “the author’s response when contacted were found to be unsatisfactory” and concluded that “these concerns would have affected the interpretation of the work” (Case Reports in Oncology, 2026).
Read that again and let it sink in.
Fenbendazole is an off-patent, over-the-counter veterinary antiparasitic. It costs pennies per dose. No pharmaceutical company owns exclusive rights to it. No one profits handsomely from its use. As reviewed by Nguyen et al. (2024), fenbendazole’s patent expired in the early 1990s, making it available as a generic drug accessible through animal supply stores and online platforms. The “financial interest” claimed against Dr. Makis — a physician helping patients with a drug that generates essentially no revenue — is not just weak. It is nonsensical.
Now let’s talk about who Dr. Markman actually is and who actually has a financial conflict of interest here.
The Real Conflict of Interest
Dr. Maurie Markman is the President of Medicine and Science at City of Hope Cancer Center. City of Hope is a multi-billion-dollar cancer treatment enterprise that generates its revenue from — you guessed it — cancer treatment. Expensive cancer treatment. Patented cancer treatment. Chemotherapy, immunotherapy, targeted biologics: treatments that cost hundreds of thousands of dollars per patient per year, that are frequently toxic, that often extend life by only weeks to months, and that leave behind a devastating legacy of cancer stem cells that drive relapse and metastasis.[/quote]